HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry.

Abstract
Kahalalide F (KF) is a novel cyclic depsipeptide anticancer drug, which has shown anticancer activity both in vitro and in vivo especially against human prostate cancer cell lines. To characterize the pharmacokinetics of KF during a phase I clinical trial in patients with androgen refractory prostate cancer, a method was developed and validated for the quantitative analysis of KF in human plasma using high-performance liquid chromatography (HPLC) coupled to positive electrospray ionization tandem mass spectrometry (ESI-MS/MS). Microbore reversed-phase liquid chromatography (LC) performed with mobile phases containing trifluoroacetic acid, an additive commonly used for separating peptides, resulted in substantial suppression of the signal for KF on ESI-MS/MS. An alternative approach employing a basic mobile phase provided an excellent response for KF when detected in the positive ion mode. Plasma samples were prepared for LC MS/MS by solid-phase extraction on C(18) cartridges. The LC separation was performed on a Zorbax Extend C(18) column (150 x 2.1 mm i.d., particle size 5 micro m) with acetonitrile -10 mM aqueous ammonia (85 : 15, v/v) as the mobile phase, at a flow-rate of 0.20 ml min(-1). A butyric acid analogue of KF was used as the internal standard. The lower limit of quantitation (LLQ) using a 500 micro l sample volume was 1 ng ml(-1) and the linear dynamic range extended to 1000 ng ml(-1). The inter-assay accuracy of the assay was -15.1% at the LLQ and between -2.68 and -9.05% for quality control solutions ranging in concentration from 2.24 to 715 ng ml(-1). The inter-assay precision was 9.91% or better at these concentrations. The analyte was stable in plasma under all relevant conditions evaluated and for a period of 16 h after reconstituting plasma extracts for LC analysis at ambient temperature.
AuthorsE Stokvis, H Rosing, L López-Lázaro, I Rodriguez, J M Jimeno, J G Supko, J H M Schellens, J H Beijnen
JournalJournal of mass spectrometry : JMS (J Mass Spectrom) Vol. 37 Issue 9 Pg. 992-1000 (Sep 2002) ISSN: 1076-5174 [Print] England
PMID12271442 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article)
CopyrightCopyright 2002 John Wiley & Sons, Ltd.
Chemical References
  • Antineoplastic Agents
  • Depsipeptides
  • Peptides
  • kahalalide F
Topics
  • Antineoplastic Agents (blood, pharmacokinetics)
  • Area Under Curve
  • Calibration
  • Chromatography, High Pressure Liquid
  • Depsipeptides
  • Drug Stability
  • Humans
  • Peptides (blood, pharmacokinetics)
  • Quality Control
  • Reference Standards
  • Reproducibility of Results
  • Spectrometry, Mass, Electrospray Ionization

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: